| XLS |
|
|
|
|
|
€ million |
Jan.–Sept. |
Jan.–Sept. |
|
Profit after tax |
927.6 |
303.3 |
|
Depreciation/amortization/impairment losses/write-ups |
996.8 |
1,037.4 |
|
Changes in inventories |
–117.1 |
93.4 |
|
Changes in trade accounts receivable |
–31.9 |
139.3 |
|
Changes in trade accounts payable |
77.3 |
192.1 |
|
Changes in provisions |
35.3 |
550.9 |
|
Changes in other assets and liabilities |
–55.5 |
–216.8 |
|
Neutralization of gain/loss on disposals of assets |
–50.0 |
–32.0 |
|
Other non-cash income and expenses |
2.6 |
6.1 |
|
Net cash flows from operating activities |
1,785.1 |
2,073.9 |
|
|
|
|
|
Investments in intangible assets |
–66.3 |
–88.0 |
|
Investments in property, plant and equipment |
–235.3 |
–181.1 |
|
Acquisitions |
–15.1 |
–4.1 |
|
Investments in non-current financial assets |
–8.4 |
–14.6 |
|
Disposal of non-current assets |
272.1 |
63.6 |
|
Purchase/sale of marketable securities |
– |
10.5 |
|
Changes in other financial assets |
–558.6 |
–370.8 |
|
Net cash flows from investing activities |
–611.7 |
–584.4 |
|
|
|
|
|
Dividend payments |
–113.1 |
–102.2 |
|
Profit transfers to E. Merck KG and changes in reserves |
–339.4 |
–92.1 |
|
Changes in liabilities to E. Merck KG |
231.8 |
–143.2 |
|
Repayment of bonds |
–750.0 |
–500.0 |
|
Changes in current and non-current financial liabilities |
4.3 |
–106.2 |
|
Net cash flows from financing activities |
–966.4 |
–943.7 |
|
|
|
|
|
Changes in cash and cash equivalents |
207.0 |
545.7 |
|
Changes in cash and cash equivalents due to currency translation |
–21.4 |
1.3 |
|
Cash and cash equivalents as of January 1 |
729.7 |
937.8 |
|
Cash and cash equivalents as of September 30 |
915.3 |
1,484.7 |